Viking Therapeutics (VKTX) has been attracting investor interest for quite a while, all thanks to the rapid progress of its pipeline candidates targeting obesity and non-alcoholic steatohepatitis (NASH) indications. This year, management reported encouraging results on its obesity and NASH drug programs. These results position the company’s pipeline candidates strongly against currently available therapies targeting these diseases. So far this year, the stock has surged 197.3% against the industry’s 6.3% de ...